HyTest Ltd  

Intelligate 1 6th Floor, Joukahaisenkatu 6
Turku,  20520

  • Booth: 102

Since 1994, we’ve developed & supplied immunological reagents for the IVD industry. We provide products for several clinical areas, and are a leading provider of reagents for cTnI immunoassays, as well as for infectious diseases like COVID-19.


  • HyTest Cardiac troponin antibodies and antigens
    Recombinant and native HyTest cardiac troponin I antibodies and antigens for high-sensitivity immunoassay development, e.g. ELISA, turbidimetry, lateral flow and magnetic particles. The antibodies can be also used in research applications such as Western blotting, immunohistochemistry, and many others....

  • Cardiac troponin I is currently considered to be the gold standard biomarker test for myocardial infarction. Moreover, cTnI measurements by a new generation of high sensitivity cTnI assays could be helpful for long-term risk stratification of different patient groups, including patients with heart failure or stable coronary artery disease.

    At HyTest, we have intensively studied troponin I for over 20 years. Based on this research, we constantly aim to develop improved antibodies from different sources, both hydridoma and recombinant, to be used in the immunoassays that are needed for accurate cardiac disease diagnostics. We have generated and tested recombinant troponins, and troponin secondary and ternary complexes, as well as several monoclonal antibodies and specific to different regions of the cTnI molecule and have tested numerous different MAb combinations to find the best pairs for a precise and sensitive cTnI immunoassay for several platforms.

  • HyTest D-dimer antibodies and antigen
    HyTest D-dimer antibodies and native antigen, produced from clotted fibrinogen, for specific D-dimer and FDP immunoassay development. We have several D-dimer antibodies specific for both D-dimer and fibrin degradation products (FDP) for both commercial and research applications....

  • D-dimer (MW 180 kDa) is the final product of fibrin degradation, which are produced during fibrinolysis in which the fibrin clots are digested by plasmin, and fibrin degradation products (FDP) of different molecular weights. Elevated levels of D-dimer have been found in the blood of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT). The elevated level of D-dimer in blood is believed to be a reliable marker of pathological coagulation. During the COVID-19 pandemic D-dimer has been commonly elevated in patients with SARS-CoV-2. It has been shown to correlate with disease severity and to be a reliable prognostic marker for hospitalization and mortality assessment in patients admitted for COVID-19.

  • HyTest SARS-CoV-2 antibodies and antigens
    HyTest SARS-CoV-2 monoclonal and polyclonal antibodies and recombinant antigens for development of COVID-19 tests. Our reagents are used in already-registered assays on different platforms including lateral flow rapid tests....

  • HyTest offers a suite of SARS-CoV-2 reagents for immunoassay development. Antibodies have been carefully characterized and tested with clinical samples. Also, we constantly monitor the emergence of new virus variants and when needed and possible, study if the mutations affect the binding properties of the antibodies. Our polyclonal antibodies can be used in combination with monoclonals; they do not recognize seasonal coronaviruses, however, they offer a broader range of specificity to SARS-CoV-2 variants. Set of recombinant antibodies can be used e.g. as positive controls.  

    We also offer reagents for the development of antibody neutralising assays: recombinant RBD and ACE2 as well as an anti-RBD antibody with strong neutralising properties suitable to be used as a calibrator in the assay.

  • HyTest Flu A/B antibodies and antigens
    HyTest Flu A and Flu B antibodies and inactivated influenza antigens suitable for assay development. ...

  • HyTest offers several Flu A and Flu B antibodies for assay development. They are suitable for ELISA type platforms and also for lateral flow. Influenza antigens could be used e.g. as positive controls in tests.